New Jersey Administrative Code › Title 10 - HUMAN SERVICES › Chapter 161B - STANDARDS FOR LICENSURE OF OUTPATIENT SUBSTANCE USE DISORDER TREATMENT FACILITIES › Subchapter 11 - OPIOID TREATMENT SERVICES › Section 10:161B-11.1 - Authority

Current through Register Vol. 56, No. 14, July 15, 2024
(a) A program applying for licensure to
				operate an opioid treatment program pursuant to these standards shall:
1. Provide written documentation that the
				applicant for licensure of the opioid treatment program has notified the
				governing authority of the municipality of the full scope of services,
				including opioid treatment, to be provided at the facility. Notification shall
				be subject to verification by DOH prior to issuance of a license to operate an
				opioid treatment program pursuant to the outpatient substance use disorder
				treatment license;
2. Be certified
				as an opioid treatment program by the Substance Abuse and Mental Health
				Services Administration (SAMHSA) and accredited by an accreditation body
				approved by SAMHSA in accordance with 42 CFR Part 8, available at
http://www.samhsa.gov/laws-regulations-guidelines/substance-use-regulations-mandates#opioid
.
				Revocation of certification by SAMHSA shall constitute the immediate withdrawal
				of licensure approval to operate an opioid treatment program by DCN&L
				;
3. Comply with all regulations
				enforced by the Drug Enforcement Administration (DEA) under 21 CFR Chapter II
				and be registered by the DEA, at 1-800-882-9539, or online at
http://www.deadiversion.usdoj.gov/index.html
;
				and State of New Jersey Department of Law and Public Safety, Drug Control Unit,
				(973) 504-6351,
http://www.njconsumeraffairs.gov/dcu/Pages/default.aspx
,
				as a Narcotic Treatment Program in accordance with
N.J.A.C.
				8:67
, before administering or dispensing opioid agonist treatment
				medications;
4. Provide services
				which meet the Federal standards set by accrediting agencies contained in 42
				CFR Part 8.12, as well as the more specific State requirements of this
				chapter;
5. Use only those opioid
				agonist treatment medications approved by the Food and Drug Administration for
				use in opioid treatment programs for the treatment of opioid
				dependence;
6. Comply with the
				publication "Medication-Assisted Treatment for Opioid Addiction in Opioid
				Treatment Programs," issued by the Center for Substance Abuse Treatment (CSAT)
				as part of the Treatment Improvement Protocol Series, TIP 43 (2005),
				incorporated herein by reference as amended and supplemented; copies are
				available from the National Clearinghouse for Alcohol and Drug Information,
				P.O. Box 2345, Rockville, MD 20847-6686, 1-800-729-6686,
http://www.cocommunity.net/agency/national-clearinghouse-alcohol-and-drug-information.html
or for online download at
				http://store.samhsa.gov/product/TIP-43-Medication-Assisted-Treatment-for-Opioid-Addiction-in-Opioid-Treatment-Prog
7. Meet all applicable local building, zoning
				and other codes for the siting of an opioid treatment program;
8. Each opioid treatment program shall
				participate in a registry or other data management system implemented by DMHAS,
				submitting information in the format prescribed by DMHAS, for the purpose of
				preventing the enrollment of clients in more than one program and facilitating
				client relocation; and
9. Opioid
				treatment programs providing detoxification shall, in addition, comply with the
				following:
i. Clients receiving short-term
				detoxification (that is, less than 30 days) shall receive services in
				accordance with
				N.J.A.C.
				10:161B-12; and
ii. Clients receiving long-term
				detoxification (that is, 30 days to 180 days) shall receive all services for
				Phase I clients required by
				10:161B-11.8 and 12.